^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MPL mutation

    i
    Other names: MPL, MPL Proto-Oncogene, Thrombopoietin Receptor, TPOR, Myeloproliferative Leukemia Virus Oncogene, Myeloproliferative Leukemia Protein, Thrombopoietin Receptor, Proto-Oncogene C-Mpl, CD110, THPOR, TPO-R, CD110 Antigen, THCYT2, C-MPL, MPLV
    Entrez ID:
    4352
    Related biomarkers:
    Mutation
    Associations

    News

    Trials
    2years
    Comparison of Clinical and Hematological Parameters of Janus Kinase 2, Calreticulin or Myeloproliferative Leukemia Virus Oncogene Mutant Essential Thrombocythemia and Triple-Negative Essential Thrombocythemia. (PubMed, Cureus)
    While the mean hemoglobin value was 12.9 g/dl in patients with triple-negative ET, it was 14.4 g/dl in patients with mutation-positive ET (p = 0.0001). Conclusion It has been observed that ET with JAK2, CALR, or MPL mutations may have different phenotypic features compared to triple-negative ET, resulting in a clinical condition consisting of older patients with a higher erythrocyte count.
    Journal
    |
    JAK2 (Janus kinase 2) • CALR (Calreticulin) • MPL (MPL Proto-Oncogene, Thrombopoietin Receptor)
    |
    JAK2 V617F • JAK2 mutation • CALR mutation • MPL mutation